Noninvasive imaging of apoptosis and its application in cancer therapeutics

Clinical Cancer Research

Volumn 14, Issue 8, 2008, Pages 2492-2501

  Coppola, Julia M ^a   Ross, Brian D ^a   Rehemtulla, Alnawaz ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; LUCIFERASE; PERIFOSINE; STAUROSPORINE; TEMOZOLOMIDE;

ANIMAL CELL; APOPTOSIS; ARTICLE; BIOLUMINESCENCE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER THERAPY; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; ENZYME ACTIVITY; GLIOMA; MOUSE; NON INVASIVE PROCEDURE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PROTEIN INTERACTION; RADIATION DOSE; REPORTER GENE; TUMOR XENOGRAFT;

ANIMALS; APOPTOSIS; CASPASE 3; CERCOPITHECUS AETHIOPS; COMBINED MODALITY THERAPY; COS CELLS; DACARBAZINE; GLIOBLASTOMA; HUMANS; LUMINESCENT MEASUREMENTS; MICE; NEOPLASM TRANSPLANTATION; TRANSPLANTATION, HETEROLOGOUS;

EID: 42249103253     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-0782     Document Type: Article

References (42)

1. Danial NN, Korsmeyer SJ. Cell death: critical control points. Cell 2004;116:205-19.
2. Jacobson MD, Weil M, Raff MC. Programmed cell death in animal development. Cell 1997;88:347-54.
3. Levine AJ, Hu W, Feng Z. The P53 pathway: what questions remain to be explored? Cell Death Differ 2006;13:1027-36.
4. Fesik SW. Promoting apoptosis as a strategy for cancer drug discovery. Nat Rev Cancer 2005;5:876-85.
5. Budihardjo I, Oliver H, Lutter M, Luo X, Wang X. Biochemical pathways of caspase activation during apoptosis. Annu Rev Cell Dev Biol 1999;15:269-90.
6. Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972;26:239-57.
7. Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science 1995;267:1456-62.
8. Nicholson DW. ICE/CED3-like proteases as therapeutic targets for the control of inappropriate apoptosis. Nat Biotechnol 1996;14:297-301.
9. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
10. Kirkin V, Joos S, Zornig M. The role of Bcl-2 family members in tumorigenesis. Biochim Biophys Acta 2004;1644:229-49.
11. Korsmeyer SJ. Chromosomal translocations in lymphoid malignancies reveal novel proto-oncogenes. Annu Rev Immunol 1992;10:785-807.
12. Pietsch EC, Humbey O, Murphy ME. Polymorphisms in the p53 pathway. Oncogene 2006;25:1602-11.
13. Okada H, Mak TW. Pathways of apoptotic and nonapoptotic death in tumour cells. Nat Rev Cancer 2004;4:592-603.
14. Luker KE, Smith MC, Luker GD, Gammon ST, Piwnica-Worms H, Piwnica-Worms D. Kinetics of regulated protein-protein interactions revealed with firefly luciferase complementation imaging in cells and living animals. Proc Natl Acad Sci U S A 2004;101:12288-93.
15. Zhang Z, Zhu W, Kodadek T. Selection and application of peptide-binding peptides. Nat Biotechnol 2000;18:71-4.
16. Thormeyer D, Ammerpohl O, Larsson O, et al. Characterization of lacZ complementation deletions using membrane receptor dimerization. Biotechniques 2003;34:346-50, 352-5.
17. Perry VH, Walker M. Amacrine cells, displaced amacrine cells and interplexiform cells in the retina of the rat. Proc R Soc Lond B Biol Sci 1980;208:415-31.
18. Forsyth PA, Cairncross JG. Treatment of malignant glioma in adults. Curr Opin Neurol 1995;8:414-8.
19. Fine HA. The basis for current treatment recommendations for malignant gliomas. J Neurooncol 1994;20:111-20.
20. Cohen MH, Johnson JR, Pazdur R. Food and Drug Administration drug approval summary: temozolomide plus radiation therapy for the treatment of newly diagnosed glioblastoma multiforme. Clin Cancer Res 2005;11:6767-71.
21. van Rijn J, Heimans JJ, van den Berg J, van derValk P, Slotman BJ. Survival of human glioma cells treated with various combination of temozolomide and Xrays. Int J Radiat Oncol Biol Phys 2000;47:779-84.
22. Crul M, Rosing H, de Klerk GJ, et al. Phase I and pharmacological study of daily oral administration of perifosine (D-21266) in patients with advanced solid tumours. Eur J Cancer 2002;38:1615-21.
23. Momota H, Nerio E, Holland EC. Perifosine inhibits multiple signaling pathways in glial progenitors and cooperates with temozolomide to arrest cell proliferationin gliomas in vivo. Cancer Res 2005;65:7429-35.
24. Chakravarti A, Erkkinen MG, Nestler U, et al. Temozolomide-mediated radiation enhancement in glioblastoma: a report on underlying mechanisms. Clin Cancer Res 2006;12:4738- 46.
25. Coppola JM, Hamilton CA, Bhojani MS, Larsen MJ, Ross BD, Rehemtulla A. Identification of inhibitors using a cell-based assay formonitoring Golgi-resident protease activity. Anal Biochem 2007;364:19-29.
26. Moffat BA, Hall DE, Stojanovska J, et al. Diffusion imaging for evaluation of tumor therapies in preclinical animal models. MAGMA 2004;17:249-59.
27. Slee EA, Zhu H, Chow SC, MacFarlane M, Nicholson DW, Cohen GM. Benzyloxycarbonyl-Val-Ala-Asp (OMe) fluoromethylketone (Z-VAD.FMK) inhibits apoptosis by blocking the processing of CPP32. Biochem J 1996;315:21-4.
28. Ozawa T, Nogami S, Sato M, Ohya Y, Umezawa Y. A fluorescent indicator for detecting protein-protein interactions in vivo based on protein splicing. Anal Chem 2000;72:5151-7.
29. Gross S, Piwnica-Worms D. Monitoring proteasome activity in cellulo and in living animals by bioluminescent imaging: technical considerations for design and use of genetically encoded reporters. Methods Enzymol 2005;399:512-30.
30. Paulmurugan R, Gambhir SS. Novel fusion protein approach for efficient high-throughput screening of small molecule-mediating protein-protein interactions in cells and living animals. Cancer Res 2005;65:7413-20.
31. Paulmurugan R, Gambhir SS. Firefly luciferase enzyme fragment complementation for imaging in cells and living animals. Anal Chem 2005;77:1295-302.
32. Momota H, Holland EC. Bioluminescence technology for imaging cell proliferation. Curr Opin Biotechnol 2005;16:681-6.
33. Zhang GJ, Kaelin WG, Jr. Bioluminescent imaging of ubiquitin ligase activity: measuring Cdk2 activity in vivo through changes in p27 turnover. Methods Enzymol 2005;399:530-49.
34. Zhang GJ, Safran M, Wei W, et al. Bioluminescent imaging of Cdk2 inhibition in vivo. Nat Med 2004;10:643-8.
35. Laxman B, Hall DE, Bhojani MS, et al. Noninvasive real-time imaging of apoptosis. Proc Natl Acad Sci U S A 2002;99:16551-5.
36. Lee KC, Hamstra DA, Bhojani MS, et al. Noninvasive molecular imaging sheds light on the synergy between 5-fluorouracil and TRAIL/Apo2L for cancer therapy. Clin Cancer Res 2007;13:1839-46.
37. Talanian RV, Quinlan C, Trautz S, et al. Substrate specificities of caspase family proteases. J Biol Chem 1997;272:9677-82.
38. Brown JM, Attardi LD. The role of apoptosis in cancer development and treatment response. Nat Rev Cancer 2005;5:231-7.
39. Gudkov AV, Komarova EA. The role of p53 in determining sensitivity to radiotherapy. Nat Rev Cancer 2003;3:117-29.
40. Seluanov A, Gorbunova V, Falcovitz A, et al. Change of the death pathway in senescent human fibroblasts in response to DNA damage is caused by an inability to stabilize p53. Mol Cell Biol 2001;21:1552-64.
41. Bocangel DB, Finkelstein S, Schold SC, Bhakat KK, Mitra S, Kokkinakis DM. Multifaceted resistance of gliomas to temozolomide. Clin Cancer Res 2002;8:2725-34.
42. Paulmurugan R, Gambhir SS. Combinatorial library screening for developing an improved split-firefly luciferase fragment-assisted complementation system for studying protein-protein interactions. Anal Chem 2007;79:2346-53.